{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:05:14Z","timestamp":1789761914125,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.111092","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:56:44Z","timestamp":1776311804000},"page":"709-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel immunotherapies for prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"George","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.urolonc.2026.111092_bib0001","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41391-024-00825-z","article-title":"Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer","volume":"28","author":"Fang","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111092_bib0002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.urolonc.2026.111092_bib0003","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.urolonc.2026.111092_bib0004","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111092_bib0005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.urolonc.2026.111092_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther Adv Urol"},{"issue":"22","key":"10.1016\/j.urolonc.2026.111092_bib0007","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169655","article-title":"Antitumor activity of AZD0754, a dnTGFbetaRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer","volume":"133","author":"Zanvit","year":"2023","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111092_bib0008","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111092_bib0009","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/ijms25010586","article-title":"Comparative evaluation of STEAP1 targeting chimeric antigen receptors with different costimulatory domains and spacers","volume":"25","author":"Jin","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111092_bib0010","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111092_bib0011","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111092_bib0012","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.094","article-title":"Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC","volume":"40","author":"McKean","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.158","article-title":"TmPSMA-02: a CD2 endodomain containing double armored PSMA CAR T with enhanced efficacy and lower immune toxicity","volume":"40","author":"Barrett","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111092_bib0015","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.098","article-title":"Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Slovin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111092_bib0017","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111092_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111092_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12967-019-02206-w","article-title":"IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J Transl Med"},{"issue":"7952","key":"10.1016\/j.urolonc.2026.111092_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111092_bib0021","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.urolonc.2026.111092_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01509-2","article-title":"Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery","author":"Murad","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111092_bib0023","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0024","volume":"40","author":"Stein","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111092_bib0025","volume":"28","author":"Bratulic","year":"2024"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111092_bib0026","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE((R)) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111092_bib0027","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of Acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","article-title":"Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Falchook","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111092_bib0029","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0030","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1200\/JCO.2021.39.15_suppl.5013","article-title":"Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"Bono","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0031","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1200\/JCO.2024.42.16_suppl.2536","article-title":"Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer","volume":"42","author":"Heitmann","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS295","article-title":"Phase 1\/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Kelly","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111092_bib0033","unstructured":"Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC. 2025; Available from:https:\/\/investors.januxrx.com\/investor-media\/news\/news-details\/2025\/Janux-Announces-Encouraging-Efficacy-and-Safety-Profile-from-Ongoing-Phase-1-Clinical-Trial-for-JANX007-in-mCRPC\/default.aspx."},{"key":"10.1016\/j.urolonc.2026.111092_bib0034","first-page":"2026","article-title":"Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC). in 2026 ASCO Genitourinary Cancers Symposium","volume":"44","author":"Bono","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111092_bib0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.urolonc.2026.111092_bib0036","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human Kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8_Supplement_2","key":"10.1016\/j.urolonc.2026.111092_bib0037","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT064","volume":"85","author":"Siddiqui","year":"2025","journal-title":"Cancer Res"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS293","article-title":"A phase 1\/2 study of nezastomig (anti-PSMA\u00d7CD28) with or without cemiplimab (anti\u2013PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC)","volume":"43","author":"Siddiqui","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.urolonc.2026.111092_bib0039","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1078-0432.CCR-22-3832","article-title":"Combination treatment with Sipuleucel-T and abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer: STAMP and STRIDE trials","volume":"29","author":"Antonarakis","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.111092_bib0040","article-title":"Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer","volume":"19","author":"Twardowski","year":"2019","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111092_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061419","article-title":"Phase II trial of sipuleucel-T and stereotactic ablative body radiation for patients with metastatic castrate-resistant prostate cancer","volume":"10","author":"Hannan","year":"2022","journal-title":"Biomedicines"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0042","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5030","article-title":"Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure","volume":"33","author":"Antonarakis","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111092_bib0043","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.321","article-title":"SymposiumA comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)","volume":"38","author":"Ross","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111092_bib0044","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.111092_bib0045","series-title":"Cell Genesys announces termination of VITAL-1 phase 3 trial of GVAX immunotherapy for prostate cancer","year":"2008"},{"key":"10.1016\/j.urolonc.2026.111092_bib0046","series-title":"Cell Genesys halts VITAL-2 GVAX trial in advanced prostate cancer","author":"Meyers","year":"2008"},{"issue":"Pt 1","key":"10.1016\/j.urolonc.2026.111092_bib0047","article-title":"Microorganism delivery of cancer vaccines","volume":"388","author":"Han","year":"2025","journal-title":"J Control Release"},{"issue":"13","key":"10.1016\/j.urolonc.2026.111092_bib0048","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5000","article-title":"Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer","volume":"43","author":"DeWeese","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111092_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.2504","article-title":"Clinical responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"43","author":"Link","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:12:13Z","timestamp":1789758733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926001031"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111092","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel immunotherapies for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}